• Spero Therapeutics' (SPRO) Overweight Rating Reaffirmed at Cantor Fitzgerald

    Source: Buzz FX / 15 Nov 2024 10:21:18   America/Chicago


    Spero Therapeutics' (SPRO) Overweight Rating Reaffirmed at Cantor Fitzgerald Written by MarketBeat November 15, 2024 Share Link copied to clipboard. Spero Therapeutics ( NASDAQ:SPRO - Get Free Report ) 's stock had its "overweight" rating r
    Read more...
Share on,